PMID- 36685554
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230201
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Investigating regulatory patterns of NLRP3 Inflammasome features and association 
      with immune microenvironment in Crohn's disease.
PG  - 1096587
LID - 10.3389/fimmu.2022.1096587 [doi]
LID - 1096587
AB  - INTRODUCTION: Crohn's disease is characterized of dysregulated inflammatory and 
      immune reactions. The role of the NOD-like receptor family, pyrin 
      domain-containing 3 (NLRP3) inflammasome in Crohn's disease remains largely 
      unknown. METHODS: The microarray-based transcriptomic data and corresponding 
      clinical information of GSE100833 and GSE16879 were obtained from the Gene 
      Expression Omnibus (GEO) database. Identification of in the NLRP3 
      inflammasome-related genes and construction of LASSO regression model. Immune 
      landscape analysis was evaluated with ssGSEA. Classification of Crohn's-disease 
      samples based on NLRP3 inflammasome-related genes with ConsensusClusterPlus. 
      Functional enrichment analysis, gene set variation analysis (GSVA) and drug-gene 
      interaction network. RESULTS: The expressions of NLRP3 inflammasome-related genes 
      were increased in diseased tissues, and higher expressions of NLRP3 
      inflammasome-related genes were correlated with generally enhanced immune cell 
      infiltration, immune-related pathways and human leukocyte antigen (HLA)-gene 
      expressions. The gene-based signature showed well performance in the diagnosis of 
      Crohn's disease. Moreover, consensus clustering identified two Crohn's disease 
      clusters based on NLRP3 inflammasome-related genes, and cluster 2 was with higher 
      expressions of the genes. Cluster 2 demonstrated upregulated activities of immune 
      environment in Crohn's disease. Furthermore, four key hub genes were identified 
      and potential drugs were explored for the treatment of Crohn's disease. 
      CONCLUSIONS: Our findings indicate that NLRP3 inflammasome and its related genes 
      could regulate immune cells and responses, as well as involve in the pathogenesis 
      of Crohn's disease from transcriptomic aspects. These findings provide in silico 
      insights into the diagnosis and treatment of Crohn's disease and might assist in 
      the clinical decision-making process.
CI  - Copyright (c) 2023 Wu, Zeng, Qiu, Chen, Zhuo, Guo, Xiang, Yang, Jiang, Leung, Lian, 
      Sha and Chen.
FAU - Wu, Huihuan
AU  - Wu H
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - School of Medicine, South China University of Technology, Guangzhou, China.
FAU - Zeng, Ruijie
AU  - Zeng R
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - School of Medicine, Shantou University Medical College, Shantou, China.
FAU - Qiu, Xinqi
AU  - Qiu X
AD  - Zhuguang Community Healthcare Center, Guangzhou, China.
FAU - Chen, Kequan
AU  - Chen K
AD  - Department of Gastroenterology, The First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - Zhuo, Zewei
AU  - Zhuo Z
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Guo, Kehang
AU  - Guo K
AD  - Department of Critical Care Medicine, The Fifth Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Xiang, Yawen
AU  - Xiang Y
AD  - Edinburgh Medical School, College of Medicine and Veterinary Medicine, University 
      of Edinburgh, Edinburgh, United Kingdom.
FAU - Yang, Qi
AU  - Yang Q
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Jiang, Rui
AU  - Jiang R
AD  - School of Medicine, South China University of Technology, Guangzhou, China.
FAU - Leung, Felix W
AU  - Leung FW
AD  - David Geffen School of Medicine, University of California Los Angeles, Los 
      Angeles, CA, United States.
FAU - Lian, Qizhou
AU  - Lian Q
AD  - Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Sha, Weihong
AU  - Sha W
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - School of Medicine, South China University of Technology, Guangzhou, China.
FAU - Chen, Hao
AU  - Chen H
AD  - Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - School of Medicine, South China University of Technology, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230105
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Inflammasomes)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
SB  - IM
MH  - Humans
MH  - *Inflammasomes/metabolism
MH  - *Crohn Disease/genetics/metabolism
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
PMC - PMC9849378
OTO - NOTNLM
OT  - Crohn's disease
OT  - NLRP3 inflammasome
OT  - drug
OT  - immune landscape
OT  - treatment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The reviewer HY declared a shared parent affiliation with 
      the author, KC, to the handling editor at the time of the review.
EDAT- 2023/01/24 06:00
MHDA- 2023/01/25 06:00
PMCR- 2022/01/01
CRDT- 2023/01/23 04:38
PHST- 2022/11/12 00:00 [received]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2023/01/23 04:38 [entrez]
PHST- 2023/01/24 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1096587 [doi]
PST - epublish
SO  - Front Immunol. 2023 Jan 5;13:1096587. doi: 10.3389/fimmu.2022.1096587. 
      eCollection 2022.